treatment in active relapsing remitting multiple sclerosis : A - PowerPoint PPT Presentation

Mar 30, 2024 •184 likes •280 views

Efficacy of alemtuzumab treatment in active relapsing remitting multiple sclerosis : A study of real world evidence ------------------------------ Mentor: Dr. Ofir Zmira Student: Alex Halpern Multiple Sclerosis Alemtuzumab Monoclonal

Efficacy of alemtuzumab treatment in active relapsing remitting multiple sclerosis : A study of real world evidence ------------------------------ Mentor: Dr. Ofir Zmira Student: Alex Halpern
Multiple Sclerosis
Alemtuzumab  Monoclonal Anti CD-52 antibody https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286943/
Previous Studies Citation: N Engl J Med 2008; 359:1786-1801
Study Design  Prospective cohort of 35 ARRMS patients  Variables followed:  1. EDSS  2. Relapse rate  3. Number and volume of MRI lesions
Results
Results P=.6177
Results Number of MRI lesions (Gadolinium) Number of MRI lesions
 Questions?

Recommend

Audit on Use of Fingolimod in Treatment of Relapsing-Remitting MS in University Hospitals

Audit on Use of Fingolimod in Treatment of Relapsing-Remitting MS in University Hospitals Coventry and Warwickshire Omar Salim ST5 Neurology Aims To assess the real world experience of Fingolimod use in University Hospitals Coventry

630 views • 27 slides

Treatment guidelines for relapsing MS and the two step approach for disease modifying

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health NHS Trust Disclosures PI of

552 views • 36 slides

BJ's symptoms are most likely consistent with 1. which of the following? Relapsing-remitting MS

C ASE P RESENTATION Maya Zeineddine, Pharm D Multiple Sclerosis Certified Specialist American University of Beirut Medical Center March 19, 2016 Amman, Jordan BJ is a 28-year-old white woman in the clinic for evaluation of significant

504 views • 26 slides

Disclosures SDN: participated in scientific advisory boards for Biogen Idec and Genzyme;

Consortium of Multiple Sclerosis Centers 2014 Annual Meeting Dallas, TX Immunogenicity with Peginterferon Beta-1a: 2-year Data from the ADVANCE Study in Relapsing-Remitting Multiple Sclerosis Scott D. Newsome, DO May 30, 2014 Scott D.

369 views • 9 slides

Visual system in MS Optic neuritis (ON): Inflammatory demyelination of the optic nerve.

6/9/2014 Multifocal Visual Evoked Potentials (mfVEP) and Ganglion Cell Inner Plexiform Thickness (GCIPT) in Relapsing Remitting Multiple Sclerosis (RRMS) Divya Narayanan, Han Cheng, Rosa Tang, Laura Frishman University of Houston Houston, TX

590 views • 12 slides

A big ig data approach for understanding environmental ri risk factors for autoimmune dis

A big ig data approach for understanding environmental ri risk factors for autoimmune dis isease fl flare Brian Reddy Trinity Health Kidney Centre / ADAPT Autoimmune disease affects 15% of the population Relapsing and Remitting

368 views • 17 slides

Diagnosis of Active TB Proper diagnostic evaluation is essential before anticipating any treatment

Active TB Section 6: Diagnosis of TB (Latent vs. Active Disease) Diagnosis of Active TB Proper diagnostic evaluation is essential before anticipating any treatment for active TB disease because the risk of unnecessary or inadequate treatment can

338 views • 3 slides

HALT MS: Study Overview Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation

Five Year Outcomes of Halt MS: High Dose HALT MS: Study Overview Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Relapsing Remitting Multiple Sclerosis Hypothesis : Intensive immunosuppressive

359 views • 7 slides

Cognitive Constructs and the Intent to Remit: Are Norms the Key to Explaining Remitting Behaviour

Cognitive Constructs and the Intent to Remit: Are Norms the Key to Explaining Remitting Behaviour of Kosovar Migrants in Germany Wiebke Meyer and Judith Mllers (Leibniz Institute of Agricultural Development in Central and Eastern Europe) and

583 views • 14 slides

OUR VISION For all patients around the world to have access to quality treatment for the chronic

RBP-6000 B UPRENORPHINE M ONTHLY D EPOT P HASE III C LINICAL R ESULTS RBP-6000 I NVESTOR E VENT J UNE 29 TH , 2017 Our vision is that all patients around the world will have access to quality treatment for the chronic relapsing conditions and

645 views • 29 slides

NUTRITION DURING CANCER TREATMENT TODAYS OUTLINE Eating Healthfully During Cancer Treatment

NUTRITION DURING CANCER TREATMENT TODAYS OUTLINE Eating Healthfully During Cancer Treatment The Nourishing Plate Supplement use considerations during active treatment Staying Hydrated During Cancer Treatment Food Safety

1.01k views • 37 slides

TREATMENT OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RAPID REMISSION OVER 48 WEEKS: DATA FROM

TREATMENT OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RAPID REMISSION OVER 48 WEEKS: DATA FROM THE AURA-LV STUDY SV Parikh 1 , WF Pendergraft 2 , JA Tumlin 3 , R Saxena 4 , N Solomons 5 , RB Huizinga 5 The Ohio State University Wexner Medical

566 views • 32 slides

$New Approach to the Presbyopia Treatment Introduction Tri-ED EDOF Concepts Active Diffractive$

New Approach to the Presbyopia Treatment Introduction Tri-ED EDOF Concepts Active Diffractive

New Approach to the Presbyopia Treatment Introduction Tri-ED EDOF Concepts Active Diffractive Optic Semi-Apodized Optic True TriFocality All in One Platform Technical Specifications First Clinical Results Competition Product Segmentation

471 views • 33 slides

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA

NCDB Special Study: Post-Active Treatment Surveillance in Prostate Cancer Webinar #4: NCRA 2017-040 5/2/17 Eileen Tonner, MS Purpose of the Study For patients who have received curative-intent prostate cancer treatment Determine whether

537 views • 21 slides

Phase III studies of direct oral anticoagulants for treatment and prevention of VTE Dabigatran,

Phase III studies of direct oral anticoagulants for treatment and prevention of VTE Dabigatran, apixaban, edoxaban and rivaroxaban Phase III VTE acute treatment studies Trial name Design Initial treatment Treatment Long-term Active with

709 views • 19 slides

The Active Card An Active Mind in an Active Body More people, More Active, More often! The

The Active Card An Active Mind in an Active Body More people, More Active, More often! The Active vision Active The Olympic Legacy 100,000 card holders by 2012 SMART card technology Improved communications for

421 views • 21 slides

Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple

Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS) Edward Fox, MD, PhD Director, MS

569 views • 20 slides

Alemtuzumab Indicated for relapsing forms of multiple sclerosis (MS) and B-cell chronic

2/3/2018 ALEMTUZUMAB ASSOCIATED LISTERIA MONOCYTOGENES MENINGITIS DURING THE TREATMENT OF MULTIPLE SCLEROSIS A Case Report CORRIE BLACK , PHARMACY STUDENT, MS ISU/UAA COP RYAN W. STEVENS , PHARMD, BCPS- PAMC THOMAS G. WADSWORTH , PHARMD, BCPS

406 views • 3 slides

Tick-borne Relapsing Fever Outbreak Arizona Infectious Disease Training and Exercise July 22,

Tick-borne Relapsing Fever Outbreak Arizona Infectious Disease Training and Exercise July 22, 2015 Mare Schumacher and Jennifer Corrigan Sunday, August 10, 2014 Hospital calls Coconino County Public Health at 5:00 p.m. Were

773 views • 48 slides

Accelerated Cord Atrophy Precedes Conversion to Secondary Progressive Disease in Relapsing

Accelerated Cord Atrophy Precedes Conversion to Secondary Progressive Disease in Relapsing Multiple Sclerosis Antje Bischof, MD Multiple Sclerosis Research Group University of California, San Francisco Background Understanding of

391 views • 8 slides

La terapia del mieloma ricaduto The natural course of MM is characterised by a pattern of

La terapia del mieloma ricaduto The natural course of MM is characterised by a pattern of remission and relapse Asymptomatic Symptomatic Relapsing Refractory ACTIVE SECOND M-protein level (g/L) 100 MYELOMA RELAPSE FIRST RELAPSED/

939 views • 45 slides

AC SC Case 79 year old active female fell while skiing These do well without surgery

AC SC Case 79 year old active female fell while skiing These do well without surgery Questions: 1. Treatment: A. Operative B. Non-operative Questions 1. Operative Treatment Choices: A. Transacromial Fixation B. Suture

256 views • 25 slides

Two Faces of Multiple Sclerosis February 8, 2017 Inflammation Neurodegeneration Relapsing MS

Two Faces of Multiple Sclerosis February 8, 2017 Inflammation Neurodegeneration Relapsing MS Progressive MS 5 0 T H A N N U A L R E C E N T A D VA N C E S I N N E U R O L O G Y B CELL THERAPY FOR MULTIPLE SCLEROSIS: A NEW DAY? Anisha

580 views • 10 slides

Clavicle Fractures AC SC Case 79 year old active female fell while skiing These do well

Clavicle Fractures AC SC Case 79 year old active female fell while skiing These do well without surgery Questions: 1. Treatment: A. Operative B. Non-operative Questions 1. Operative Treatment Choices: A. Transacromial

1.38k views • 55 slides